<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="acpp" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">acpp</book-part-id>
      <title-group>
        <title>Andersen-Tawil Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Statland</surname>
            <given-names>Jeffrey M</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Department of Neurology <break/>University of Kansas Medical Center <break/>Kansas City, Kansas</aff>
          <email>jstatland@kumc.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tawil</surname>
            <given-names>Rabi</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Department of Neurology <break/>University of Rochester Medical Center <break/>Rochester, New York</aff>
          <email>rabi_tawil@urmc.rochester.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Venance</surname>
            <given-names>Shannon L</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Department of Clinical Neurological Sciences <break/>London Health Sciences Centre <break/>University of Western Ontario <break/>London, Ontario</aff>
          <email>shannon.venance@lhsc.on.ca</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>22</day>
          <month>11</month>
          <year>2004</year>
        </date>
        <date date-type="updated">
          <day>6</day>
          <month>8</month>
          <year>2015</year>
        </date>
        <date date-type="revised">
          <day>3</day>
          <month>9</month>
          <year>2015</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="als-overview" document-type="chapter">Amyotrophic Lateral Sclerosis Overview</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="androgen" document-type="chapter">Androgen Insensitivity Syndrome</related-object>
      <abstract id="acpp.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Andersen-Tawil syndrome (ATS) is characterized by a triad of episodic flaccid muscle weakness (i.e., periodic paralysis), ventricular arrhythmias and prolonged QT interval, and anomalies including low-set ears, widely spaced eyes, small mandible, fifth-digit clinodactyly, syndactyly, short stature, and scoliosis. Affected individuals present in the first or second decade with either cardiac symptoms (palpitations and/or syncope) or weakness that occurs spontaneously following prolonged rest or following rest after exertion. Mild permanent weakness is common. Mild learning difficulties and a distinct neurocognitive phenotype (i.e., deficits in executive function and abstract reasoning) have been described.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of ATS is suspected in an individual with characteristic clinical and ECG findings. A pathogenic variant in <italic toggle="yes">KCNJ2</italic>, encoding the inward rectifier potassium channel 2 protein (Kir2.1), is identified in approximately 60% of individuals with ATS. The presence of a pathogenic variant in <italic toggle="yes">KCNJ2</italic> confirms the diagnosis.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations</italic>: For episodic weakness: if serum potassium concentration is low (&#x0003c;3.0 mmol/L), administration of oral potassium (20-30 mEq/L) every 15-30 minutes (not to exceed 200 mEq in a 12-hour period) until the serum concentration normalizes; if a relative drop in serum potassium within the normal range causes episodic paralysis, an individual potassium replacement regimen with a goal of maintaining serum potassium levels in the high range of normal can be considered; if serum potassium concentration is high, ingesting carbohydrates or continuing mild exercise may shorten the attack.</p>
          <p><italic toggle="yes">Prevention of primary manifestations</italic>: Reduction in frequency and severity of episodic attacks of weakness with lifestyle/dietary modification to avoid known triggers; use of carbonic anhydrase inhibitors; daily use of slow-release potassium supplements; implantable cardioverter-defibrillator for those with tachycardia-induced syncope. Empiric treatment with flecainide should be considered for significant, frequent ventricular arrhythmias in the setting of reduced left ventricular function.</p>
          <p><italic toggle="yes">Prevention of secondary complications</italic>: Cautious use of antiarrhythmic drugs (particularly class I drugs) that may paradoxically exacerbate the neuromuscular symptoms.</p>
          <p><italic toggle="yes">Surveillance</italic>: Annual screening of asymptomatic individuals with a <italic toggle="yes">KCNJ2</italic> pathogenic variant with a 12-lead ECG and 24-hour Holter monitoring.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid</italic>: Medications known to prolong QT intervals; salbutamol inhalers (may exacerbate cardiac arrhythmias); thiazide and other potassium-wasting diuretics (may provoke drug-induced hypokalemia and could aggravate the QT interval).</p>
          <p><italic toggle="yes">Evaluation of relatives at risk</italic>: Molecular genetic testing if the pathogenic variant is known, otherwise detailed neurologic and cardiologic evaluation, 12-lead ECG, and 24-hour Holter monitoring can be done to reduce morbidity and mortality through early diagnosis and treatment in at-risk relatives.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>ATS is inherited in an autosomal dominant manner. At least 50% of individuals diagnosed with ATS have an affected parent. Up to 50% of affected individuals have ATS as the results of a <italic toggle="yes">de novo</italic> pathogenic variant. Each child of an individual with ATS has a 50% chance of inheriting the disorder. Prenatal diagnosis for pregnancies at increased risk is possible if the <italic toggle="yes">KCNJ2</italic> pathogenic variant has been identified in an affected family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="acpp.Diagnosis">
        <title>Diagnosis</title>
        <sec id="acpp.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Andersen-Tawil syndrome (ATS) <bold>should be suspected</bold> in individuals with EITHER A OR B:</p>
          <list list-type="alpha-upper">
            <list-item>
              <label>A</label>
              <p>Two of the following three criteria:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Periodic paralysis</p>
                </list-item>
                <list-item>
                  <p>Symptomatic cardiac arrhythmias or electrocardiographic evidence of enlarged U-waves, ventricular ectopy, or a prolonged QTc or QUc interval</p>
                </list-item>
                <list-item>
                  <p>Characteristic facies, dental anomalies, small hands and feet, AND at least two of the following:</p>
                  <list list-type="bullet">
                    <list-item>
                      <p>Low-set ears</p>
                    </list-item>
                    <list-item>
                      <p>Widely spaced eyes</p>
                    </list-item>
                    <list-item>
                      <p>Small mandible</p>
                    </list-item>
                    <list-item>
                      <p>Fifth-digit clinodactyly</p>
                    </list-item>
                    <list-item>
                      <p>Syndactyly of toes 2 and 3</p>
                    </list-item>
                  </list>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <label>B</label>
              <p>One of the above three criteria AND at least one other family member who meets two of the three criteria [<xref ref-type="bibr" rid="acpp.REF.tawil.1994.326">Tawil et al 1994</xref>, <xref ref-type="bibr" rid="acpp.REF.sansone.1997.305">Sansone et al 1997</xref>, <xref ref-type="bibr" rid="acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</xref>]</p>
            </list-item>
          </list>
        </sec>
        <sec id="acpp.Supportive_Findings">
          <title>Supportive Findings</title>
          <p>Individuals with either episodic weakness or cardiac symptoms require careful evaluation by a neurologist and/or cardiologist as well as measurement of serum potassium concentration (baseline and during attacks of flaccid paralysis), a 12-lead ECG, a 24-hour Holter monitor, and possibly the long exercise protocol.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Serum potassium concentration</bold> during episodes of weakness may be elevated, normal, or, most commonly, reduced (&#x0003c;3.5 mmol/U) [<xref ref-type="bibr" rid="acpp.REF.tawil.1994.326">Tawil et al 1994</xref>, <xref ref-type="bibr" rid="acpp.REF.sansone.1997.305">Sansone et al 1997</xref>, <xref ref-type="bibr" rid="acpp.REF.can_n.1999.147">Can&#x000fa;n et al 1999</xref>, <xref ref-type="bibr" rid="acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Routine nerve conduction electrophysiology</bold> is normal between episodes. A more sensitive electrophysiologic study, the long exercise protocol, may reveal an immediate post-exercise increment followed by an abnormal decrement in the compound motor action potential amplitude (&#x0003e;40%) [<xref ref-type="bibr" rid="acpp.REF.katz.1999.352">Katz et al 1999</xref>] or area (&#x0003e;50%) 20-40 minutes post-exercise [<xref ref-type="bibr" rid="acpp.REF.kuntzer.2000.1089">Kuntzer et al 2000</xref>, <xref ref-type="bibr" rid="acpp.REF.fournier.2004.650">Fournier et al 2004</xref>]. In a study of 11 individuals with ATS, 82% met long-exercise amplitude decrement criteria for abnormal testing [<xref ref-type="bibr" rid="acpp.REF.tan.2011.328">Tan et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Electrocardiogram</bold> may reveal characteristic abnormalities including prominent U waves, prolonged Q-U intervals, premature ventricular contractions, polymorphic ventricular tachycardia, and bidirectional ventricular tachycardia [<xref ref-type="bibr" rid="acpp.REF.zhang.2005.2720">Zhang et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>24-hour Holter monitoring</bold> is important to document the presence, frequency, and duration of ventricular tachycardia (VT) and the presence or absence of associated symptoms.</p>
            </list-item>
          </list>
        </sec>
        <sec id="acpp.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of ATS <bold>is established</bold> in a proband with the above clinical criteria and/or when a heterozygous pathogenic variant is identified in <italic toggle="yes">KCNJ2</italic> (see <xref ref-type="table" rid="acpp.T.molecular_genetic_testing_used_in">Table 1</xref>).</p>
          <p>Molecular testing approaches can include <bold>serial single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more conprehensive</bold>
<bold>genomic testing</bold>:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Serial single-gene testing</bold> can be considered if (1) mutation of a particular gene accounts for a large proportion of the disease <bold>or</bold> (2) clinical findings, laboratory findings, ancestry, or other factors indicate that mutation of a particular gene is most likely. Sequence analysis of the gene of interest is performed first, followed by gene-targeted deletion/duplication analysis if no pathogenic variant is found.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">KCNJ2, KCNJ5,</italic> and other genes of interest (see <xref ref-type="sec" rid="acpp.Differential_Diagnosis">Differential Diagnosis</xref> and <related-object link-type="booklink" source-id="gene" document-id="rws" document-type="chapter">Long QT Syndrome</related-object>) may also be considered. Note: The genes included and sensitivity of multi-gene panels vary by laboratory and over time.</p>
              <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
            </list-item>
            <list-item>
              <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing, genome sequencing, and mitochondrial sequencing may be considered if serial single-gene testing (and/or use of a multi-gene panel) fails to confirm a diagnosis in an individual with features of ATS.</p>
              <p>For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <table-wrap id="acpp.T.molecular_genetic_testing_used_in" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Andersen-Tawil Syndrome</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">KCNJ2</italic>
                  </td>
                  <td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">~60%&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>6</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown&#x000a0;<sup>7</sup></td>
                  <td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                  <td headers="hd_h_acpp.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="acpp.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="acpp" object-id="acpp.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="acpp.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="acpp.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="acpp.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="acpp.TF.1.4">
                <label>4. </label>
                <p><xref ref-type="bibr" rid="acpp.REF.plaster.2001.511">Plaster et al [2001]</xref>, <xref ref-type="bibr" rid="acpp.REF.ai.2002.2592">Ai et al [2002]</xref>, <xref ref-type="bibr" rid="acpp.REF.andelfinger.2002.663">Andelfinger et al [2002]</xref>, <xref ref-type="bibr" rid="acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al [2002]</xref>, <xref ref-type="bibr" rid="acpp.REF.donaldson.2003.1811">Donaldson et al [2003]</xref>, <xref ref-type="bibr" rid="acpp.REF.hosaka.2003.409">Hosaka et al [2003]</xref></p>
              </fn>
              <fn id="acpp.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="acpp.TF.1.6">
                <label>6. </label>
                <p>Large deletions of <italic toggle="yes">KCNJ2</italic> are reported [<xref ref-type="bibr" rid="acpp.REF.lestner.2012.700">Lestner et al 2012</xref>, <xref ref-type="bibr" rid="acpp.REF.vergult.2012.534">Vergult et al 2012</xref>, <xref ref-type="bibr" rid="acpp.REF.marquisnicholson.2014.17">Marquis-Nicholson et al 2014</xref>]. The prevalence of large deletions is unknown.</p>
              </fn>
              <fn id="acpp.TF.1.7">
                <label>7. </label>
                <p>One individual with periodic paralysis, ventricular arrhythmias, no history of hypertension, and normal plasma aldosterone levels was found to have a <xref ref-type="table" rid="acpp.T.kcnj5_pathogenic_variants_discuss">p.Gly387Thr</xref> variant in <italic toggle="yes">KCNJ5.</italic> Of individuals with suspected ATS in whom a <italic toggle="yes">KCNJ2</italic> pathogenic variant was not identified, 1/21 had a <xref ref-type="table" rid="acpp.T.kcnj5_pathogenic_variants_discuss">p.Thr158Ala</xref>
<italic toggle="yes">KCNJ5</italic> variant identified [<xref ref-type="bibr" rid="acpp.REF.kokunai.2014.1058">Kokunai et al 2014</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="acpp.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="acpp.Clinical_Description">
          <title>Clinical Description</title>
          <p>Andersen-Tawil syndrome (ATS) is characterized by a triad of features:</p>
          <list list-type="bullet">
            <list-item>
              <p>Episodic flaccid muscle weakness</p>
            </list-item>
            <list-item>
              <p>Ventricular arrhythmias and prolonged QT interval</p>
            </list-item>
            <list-item>
              <p>Distinctive dysmorphic features</p>
            </list-item>
          </list>
          <p>Affected individuals present initially with either periodic paralysis or cardiac symptoms (palpitations and/or syncope) in the first or second decade [<xref ref-type="bibr" rid="acpp.REF.tawil.1994.326">Tawil et al 1994</xref>, <xref ref-type="bibr" rid="acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</xref>]; however, prospective standardized natural history data are not yet available. The phenotype is highly variable. Approximately 60% of affected individuals manifest the complete triad of cardinal features and up to 80% express two of the three cardinal features [<xref ref-type="bibr" rid="acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</xref>, <xref ref-type="bibr" rid="acpp.REF.haruna.2007.208">Haruna et al 2007</xref>].</p>
          <p><bold>Weakness.</bold> Intermittent weakness occurs spontaneously, or alternatively may be triggered by prolonged rest or rest following exertion. The attack frequency, duration, and severity are variable between and within affected individuals. Mild permanent weakness is common [<xref ref-type="bibr" rid="acpp.REF.tawil.1994.326">Tawil et al 1994</xref>, <xref ref-type="bibr" rid="acpp.REF.sansone.1997.305">Sansone et al 1997</xref>, <xref ref-type="bibr" rid="acpp.REF.can_n.1999.147">Can&#x000fa;n et al 1999</xref>, <xref ref-type="bibr" rid="acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</xref>]. Affected individuals can develop fixed proximal weakness over time.</p>
          <p><bold>Ventricular arrhythmias</bold> including bidirectional ventricular tachycardia (VT), polymorphic VT, and multifocal premature ventricular contractions may be asymptomatic, or may manifest (most commonly) as palpitations. Less common symptomatic presentations include syncope, cardiac arrest, or sudden death [<xref ref-type="bibr" rid="acpp.REF.andelfinger.2002.663">Andelfinger et al 2002</xref>, <xref ref-type="bibr" rid="acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</xref>, <xref ref-type="bibr" rid="acpp.REF.donaldson.2003.1811">Donaldson et al 2003</xref>]. While the ECG may reveal a long QTc (LQT) interval, characteristic T-U patterns including enlarged U waves, a wide T-U junction, and prolonged terminal T-wave downslope distinguish ATS from other LQT syndromes [<xref ref-type="bibr" rid="acpp.REF.zhang.2005.2720">Zhang et al 2005</xref>, <xref ref-type="bibr" rid="acpp.REF.haruna.2007.208">Haruna et al 2007</xref>]. A large case series found no significant difference in the incidence of ventricular tachyarrhythmias between individuals with typical and atypical presentations of ATS [<xref ref-type="bibr" rid="acpp.REF.kimura.2012.344">Kimura et al 2012</xref>]. A retrospective multicenter French study of 36 individuals with ATS followed for an average of 9.5 years, reported no deaths in follow up; four individuals experienced syncope and one individual had a non-fatal cardiac arrest [<xref ref-type="bibr" rid="acpp.REF.delannoy.2013.1805">Delannoy et al 2013</xref>].</p>
          <p><bold>Dilated cardiomyopathy</bold> was observed in two of three affected individuals in a single kindred with the <xref ref-type="table" rid="acpp.T.kcnj2_pathogenic_variants_discuss">p.Arg218Trp</xref> pathogenic variant [<xref ref-type="bibr" rid="acpp.REF.schoonderwoerd.2006.1346">Schoonderwoerd et al 2006</xref>]; whether this is an uncommon phenotypic manifestation or a consequence of chronic tachycardia remains to be seen [<xref ref-type="bibr" rid="acpp.REF.tristanifirouzi.2006.1351">Tristani-Firouzi 2006</xref>].</p>
          <p><bold>Distinctive physical features</bold> recognized initially included low-set ears, widely spaced eyes, small mandible, fifth-digit clinodactyly, syndactyly, short stature, broad nasal root, and scoliosis [<xref ref-type="bibr" rid="acpp.REF.andersen.1971.559">Andersen et al 1971</xref>, <xref ref-type="bibr" rid="acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</xref>, <xref ref-type="bibr" rid="acpp.REF.donaldson.2003.1811">Donaldson et al 2003</xref>]. Dental enamel discoloration was noted in two kindreds with the <xref ref-type="table" rid="acpp.T.kcnj2_pathogenic_variants_discuss">p.Gly300Asp</xref> and p.Arg218Trp pathogenic variants [<xref ref-type="bibr" rid="acpp.REF.davies.2005.1083">Davies et al 2005</xref>].</p>
          <p>Detailed, prospectively collected data in ten individuals with confirmed <italic toggle="yes">KCNJ2</italic> pathogenic variants have expanded the phenotype to include a characteristic facies and dental and skeletal anomalies [<xref ref-type="bibr" rid="acpp.REF.yoon.2006a.312">Yoon et al 2006a</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>Characteristic facies include broad forehead, short palpebral fissures, wide nasal bridge with bulbous nose, hypoplasia of maxilla and mandible, thin upper lip, and a triangular face.</p>
            </list-item>
            <list-item>
              <p>Dental findings include (among others) persistent primary dentition, multiple missing teeth (oligodontia), and dental crowding.</p>
            </list-item>
            <list-item>
              <p>Skeletal findings include mild syndactyly of toes 2 and 3 as well as fifth-digit clinodactyly.</p>
            </list-item>
            <list-item>
              <p>Novel findings include small hands and feet (&#x0003c;10th centile for age) and joint laxity.</p>
            </list-item>
          </list>
          <p>Note: Isolated reports of <bold>renal anomalies</bold> include unilateral hypoplastic kidney [<xref ref-type="bibr" rid="acpp.REF.andelfinger.2002.663">Andelfinger et al 2002</xref>] and renal tubular defect [<xref ref-type="bibr" rid="acpp.REF.davies.2005.1083">Davies et al 2005</xref>].</p>
          <p><bold>Mild learning difficulties</bold> have been described [<xref ref-type="bibr" rid="acpp.REF.davies.2005.1083">Davies et al 2005</xref>]. A distinct neurocognitive phenotype (i.e., deficits in executive function and abstract reasoning) has been recognized in individuals with a <italic toggle="yes">KCNJ2</italic> pathogenic variant despite IQ levels similar to those of their unaffected sibs [<xref ref-type="bibr" rid="acpp.REF.yoon.2006b.1703">Yoon et al 2006b</xref>].</p>
          <p><bold>Afebrile seizures</bold> occurring only in infancy were reported in 4/23 (17%) of a Japanese cohort with molecularly confirmed ATS [<xref ref-type="bibr" rid="acpp.REF.haruna.2007.208">Haruna et al 2007</xref>].</p>
        </sec>
        <sec id="acpp.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Whether a <italic toggle="yes">KCNJ2</italic> pathogenic variant is present or not, individuals with clinically defined ATS are phenotypically indistinguishable [<xref ref-type="bibr" rid="acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</xref>, <xref ref-type="bibr" rid="acpp.REF.donaldson.2003.1811">Donaldson et al 2003</xref>].</p>
          <p>In a case series that evaluated for <italic toggle="yes">KCNJ2</italic> pathogenic variants in individuals with typical (&#x0003e;2 ATS features) and atypical (only 1 ATS feature or catecholaminergic polymorphic ventricular tachycardia [CPVT]) features of ATS, mutation-positive rates were 75% (15/20) in those with typical ATS, 71% (5/7) in those with the cardiac phenotype alone, 100% (2/2) in those with periodic paralysis, and 7% (2/28) in those with CPVT [<xref ref-type="bibr" rid="acpp.REF.kimura.2012.344">Kimura et al 2012</xref>].</p>
          <p>In a single large kindred with the <italic toggle="yes">KCNJ2</italic>
<xref ref-type="table" rid="acpp.T.kcnj2_pathogenic_variants_discuss">p.Arg67Trp</xref> pathogenic variant, periodic paralysis was observed only in men, cardiac symptoms only in women, and congenital anomalies in both [<xref ref-type="bibr" rid="acpp.REF.andelfinger.2002.663">Andelfinger et al 2002</xref>]. However, this apparent sex-limited bias in clinical presentation has not been confirmed [<xref ref-type="bibr" rid="acpp.REF.donaldson.2003.1811">Donaldson et al 2003</xref>, <xref ref-type="bibr" rid="acpp.REF.davies.2005.1083">Davies et al 2005</xref>].</p>
          <p>A large five-generation family was found to have a deletion in <italic toggle="yes">KCNJ2</italic> (<xref ref-type="table" rid="acpp.T.kcnj2_pathogenic_variants_discuss">c.271_282del12;p.Ala91_Leu94del</xref>) and more severe cardiac manifestations, including 4/10 individuals receiving an implantable cardioverter-defibrillator and 5/10 reporting life-threatening ventricular arrhythmias in childhood [<xref ref-type="bibr" rid="acpp.REF.fernlund.2013.471">Fernlund et al 2013</xref>]. These individuals had characteristic mild dysmorphic features, but only one had periodic paralysis.</p>
          <p>Two pathogenic variants in <italic toggle="yes">KCNJ2</italic> associated with a reduction in Kir2.1 current but without a dominant-negative effect on normal channels (<xref ref-type="table" rid="acpp.T.kcnj2_pathogenic_variants_discuss">p.Asn318Ser</xref> and <xref ref-type="table" rid="acpp.T.kcnj2_pathogenic_variants_discuss">p.Trp322Cys</xref>) were described in three individuals with an isolated cardiac phenotype: with premature ventricular contractions, ventricular tachycardia, or ventricular fibrillation [<xref ref-type="bibr" rid="acpp.REF.limberg.2013.353">Limberg et al 2013</xref>].</p>
        </sec>
        <sec id="acpp.Penetrance">
          <title>Penetrance</title>
          <p>Non-penetrance is evident in 6%-20% of individuals with an identifiable pathogenic variant [<xref ref-type="bibr" rid="acpp.REF.andelfinger.2002.663">Andelfinger et al 2002</xref>, <xref ref-type="bibr" rid="acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</xref>, <xref ref-type="bibr" rid="acpp.REF.donaldson.2003.1811">Donaldson et al 2003</xref>].</p>
        </sec>
        <sec id="acpp.Nomenclature">
          <title>Nomenclature</title>
          <p>Although listed in OMIM, the following names for ATS are no longer in clinical use:</p>
          <list list-type="bullet">
            <list-item>
              <p>Periodic paralysis, potassium-sensitive cardiodysrhythmic type</p>
            </list-item>
            <list-item>
              <p>Andersen cardiodysrhythmic periodic paralysis</p>
            </list-item>
          </list>
        </sec>
        <sec id="acpp.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence is not known. ATS is diagnosed in fewer than 10% of individuals with primary periodic paralysis. The incidence of periodic paralysis is also unknown and estimated to be at most 1:100,000.</p>
        </sec>
      </sec>
      <sec id="acpp.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">KCNJ2</italic>.</p>
      </sec>
      <sec id="acpp.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Andersen-Tawil syndrome (ATS) should be considered in any individual presenting with periodic paralysis and ventricular arrhythmias or enlarged U waves. Individuals with either episodic weakness or cardiac symptoms require careful evaluation by a neurologist and/or cardiologist as well as measurement of serum potassium concentration (baseline and during attacks of flaccid paralysis), a 12-lead ECG, a 24-hour Holter monitor, and possibly the long exercise protocol. The differential diagnosis depends on the initial presentation and includes the primary and secondary periodic paralyses, thyrotoxic periodic paralysis, and conditions associated with long QT.</p>
        <p>
          <bold>Episodes of flaccid paralysis</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="hpp" document-type="chapter">Hypokalemic periodic paralysis</related-object> is the most common periodic paralysis. Affected individuals may experience paralytic episodes with concomitant hypokalemia (&#x0003c;2.5 mmol/L), and occasionally may develop late-onset proximal myopathy. The paralytic attacks are characterized by reversible flaccid paralysis usually leading to paraparesis or tetraparesis but typically sparing the respiratory muscles and heart. The onset, duration, and severity of attacks, with the associated triggers, are similar to those in individuals with ATS. Weakness is improved with oral potassium ingestion. The cardiac and dysmorphic features of ATS are, however, absent in individuals with hypokalemic periodic paralysis. Molecular testing identifies pathogenic variants in <italic toggle="yes">CACNA1S</italic> or <italic toggle="yes">SCN4A</italic> in approximately 80% of affected individuals after secondary causes such as thyrotoxicosis, diuretic use, and renal (e.g., hyperaldosteronism, distal tubular acidosis) or gastrointestinal (e.g., vomiting, diarrheal illness) causes have been ruled out. Inheritance is autosomal dominant.</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="hyper-pp" document-type="chapter">Hyperkalemic periodic paralysis</related-object> is characterized by episodes of flaccid paralysis associated with normal or elevated ictal serum potassium concentrations (&#x0003e;5.0 mmol/U) and aggravated by potassium ingestion. Onset is in the first decade; episodes are briefer than those that occur in individuals with hypokalemic periodic paralysis. Electrical myotonia is evident in 50% of affected individuals. The cardiac and dysmorphic features of ATS are absent. Molecular testing reveals pathogenic variants in <italic toggle="yes">SCN4A</italic> in approximately 60% of individuals. Inheritance is autosomal dominant. Secondary forms of hyperkalemic periodic paralysis to rule out include adrenal insufficiency, hypoaldosteronism, and adverse effects of certain medications (e.g., ACE inhibitors, spironolactone, nonsteroidal anti-inflammatory drugs).</p>
          </list-item>
          <list-item>
            <p><bold>Thyrotoxic periodic paralysis</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/188580">188580</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/613239">613239</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/614834">614834</ext-link>) is a consideration in any individual with severe weakness and marked hypokalemia. Men, particularly Asians, are affected in greater numbers; however, thyrotoxic periodic paralysis may be seen in all races. Diagnosis is established by measurement of serum thyroid-stimulating hormone (TSH), T4, and T3 concentrations. A pathogenic variant in an inwardly rectifying potassium (Kir) channel (encoded by <italic toggle="yes">KCNJ18</italic>) was identified in approximately one third of affected individuals in one series [<xref ref-type="bibr" rid="acpp.REF.ryan.2010.88">Ryan et al 2010</xref>].</p>
          </list-item>
        </list>
        <p><bold>Long QT syndromes.</bold> See <related-object link-type="booklink" source-id="gene" document-id="rws" document-type="chapter">Long QT Syndrome</related-object>, a review of similar phenotypes that are genetically diverse.</p>
        <p><bold>Palpitations, syncope, or cardiac arrest.</bold> Syncopal episodes are often interpreted as a neurologic problem rather than arrhythmia. Physical examination and ECG should be part of the evaluation of syncope. Bidirectional ventricular tachycardia demonstrated on ECG may be seen with ATS, digitalis toxicity, and <related-object link-type="booklink" source-id="gene" document-id="cvt" document-type="chapter">catecholaminergic polymorphic ventricular tachycardia</related-object> (CPVT). A normal resting ECG with exercise-induced polymorphic arrhythmias is a clue to CPVT. Pathogenic variants in <italic toggle="yes">RYR2</italic> or <italic toggle="yes">CASQ2</italic> are causative. Inheritance is autosomal dominant [<xref ref-type="bibr" rid="acpp.REF.tristanifirouzi.2010.289">Tristani-Firouzi &#x00026; Etheridge 2010</xref>].</p>
      </sec>
      <sec id="acpp.Management">
        <title>Management</title>
        <sec id="acpp.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with Andersen-Tawil syndrome (ATS), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Baseline assessments by a neurologist and cardiologist familiar with periodic paralysis and long QT (LQT) respectively</p>
            </list-item>
            <list-item>
              <p>Serum potassium concentrations at baseline and during attacks of weakness</p>
            </list-item>
            <list-item>
              <p>12-lead ECG and 24-hour Holter monitor</p>
            </list-item>
            <list-item>
              <p>Electrophysiologic studies including the long exercise protocol [<xref ref-type="bibr" rid="acpp.REF.kuntzer.2000.1089">Kuntzer et al 2000</xref>, <xref ref-type="bibr" rid="acpp.REF.fournier.2004.650">Fournier et al 2004</xref>]</p>
            </list-item>
            <list-item>
              <p>Verification that serum TSH concentration is within normal limits</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="acpp.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Management of individuals with ATS requires the coordinated input of a neurologist familiar with the treatment of periodic paralysis and a cardiologist familiar with the treatment of cardiac arrhythmias. To date, no randomized clinical therapeutic trials have been conducted on ATS.</p>
          <p>Management of attacks of episodic weakness depends on the associated serum potassium concentration:</p>
          <list list-type="bullet">
            <list-item>
              <p>If the serum potassium concentration is low (&#x0003c;3.0 mmol/L), administration of oral potassium (20-30 mEq/L) every 15-30 minutes (not to exceed 200 mEq in a 12-hour period) until the serum concentration normalizes often shortens the attack. As dysphagia is almost never a problem during attacks of paralysis, oral potassium replacement is the safest route. If intravenous potassium replacement is needed, a 5% mannitol solution instead of a saline or glucose solution (both of which may exacerbate weakness) is recommended. Close monitoring of serum potassium concentrations and ECG is necessary during potassium replacement therapy in an emergency setting to avoid secondary hyperkalemia.</p>
            </list-item>
            <list-item>
              <p>Whether a relative drop in serum potassium within the normal range causes episodic paralysis is not clear. If such cases are suspected, affected individuals can work with their physician to devise an individual potassium replacement regimen, with a goal of maintaining serum potassium levels in the high range of normal.</p>
            </list-item>
            <list-item>
              <p>Attacks of weakness when serum potassium concentration is high usually resolve within 60 minutes. Episodes may be shortened by ingesting carbohydrates or continuing mild exercise. Intravenous calcium gluconate is rarely necessary for management in an individual seen in an emergency setting.</p>
            </list-item>
          </list>
          <p>Vasovagal syncope in individuals with ATS mandates a careful cardiology assessment [<xref ref-type="bibr" rid="acpp.REF.airey.2009.1814">Airey et al 2009</xref>].</p>
        </sec>
        <sec id="acpp.Prevention_of_Primary_Manifestation">
          <title>Prevention of Primary Manifestations</title>
          <p>Prophylactic treatment aimed at reduction of attack frequency and severity can be achieved, as in other forms of periodic paralysis, with the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Lifestyle and dietary modification to avoid known triggers</p>
            </list-item>
            <list-item>
              <p>Use of carbonic anhydrase inhibitors (acetazolamide 250-500 mg/1-2x/day or dichlorphenamide 50-100 mg/1-2x/day)</p>
            </list-item>
            <list-item>
              <p>Daily use of slow-release potassium supplements, which may also be helpful in controlling attack rates in individuals prone to hypokalemia. Elevating the serum potassium concentration (&#x0003e;4 mEq/L) has the added benefit of narrowing the QT interval, thus reducing the risk of LQT-associated arrhythmias.</p>
            </list-item>
            <list-item>
              <p>An implantable cardioverter-defibrillator in individuals with tachycardia-induced syncope [<xref ref-type="bibr" rid="acpp.REF.chun.2004.235">Chun et al 2004</xref>]</p>
            </list-item>
            <list-item>
              <p>Empiric treatment with flecainide [<xref ref-type="bibr" rid="acpp.REF.b_kenkamp.2007.508">B&#x000f6;kenkamp et al 2007</xref>, <xref ref-type="bibr" rid="acpp.REF.fox.2008.1006">Fox et al 2008</xref>, <xref ref-type="bibr" rid="acpp.REF.pellizz_n.2008.95">Pellizz&#x000f3;n et al 2008</xref>] should be considered for significant, frequent ventricular arrhythmias in the setting of reduced left ventricular function [<xref ref-type="bibr" rid="acpp.REF.tristanifirouzi.2010.289">Tristani-Firouzi &#x00026; Etheridge 2010</xref>]. A prospective open label study in ten individuals with ATS and a confirmed <italic toggle="yes">KCNJ2</italic> pathogenic variant tested the effect of flecainide, a type 1c antiarrhythmic, for the prevention of cardiac arrhythmias [<xref ref-type="bibr" rid="acpp.REF.miyamoto.2015.596">Miyamoto et al 2015</xref>]. Outcomes included a 24-hour Holter monitor before and after treatment, and a treadmill exercise test. Flecainide was found to significantly reduce the number of ventricular arrhythmias seen on Holter monitor, and to suppress exercise-induced ventricular arrhythmias. Individuals were then followed for a mean of 23 months and no syncope or cardiac arrest was documented. The study concluded that flecainide may reduce cardiac arrhythmias in ATS; however, the ultimate benefit of flecainide for prevention of medically significant cardiac arrhythmias is still unknown.</p>
            </list-item>
          </list>
        </sec>
        <sec id="acpp.Prevention_of_Secondary_Complicatio">
          <title>Prevention of Secondary Complications</title>
          <p>Cardiologists should be aware that some antiarrhythmic drugs, particularly Class I drugs, may paradoxically exacerbate the neuromuscular symptoms and should be used cautiously in individuals with ATS.</p>
          <p>Although <related-object link-type="booklink" source-id="gene" document-id="mhs" document-type="chapter">malignant hyperthermia</related-object> has not been reported in ATS, appropriate anesthetic precautions should be undertaken as with individuals with other forms of periodic paralysis.</p>
        </sec>
        <sec id="acpp.Surveillance">
          <title>Surveillance</title>
          <p>For asymptomatic individuals with a <italic toggle="yes">KCNJ2</italic> pathogenic variant, annual screening including a 12-lead ECG and 24-hour Holter monitoring is desirable, followed by referral to a cardiologist if abnormalities are identified.</p>
        </sec>
        <sec id="acpp.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Affected individuals should avoid medications known to prolong QT intervals. See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.crediblemeds.org/everyone/composite-list-all-qtdrugs/">CredibleMeds<sup>&#x000ae;</sup></ext-link> for a complete and updated list.</p>
          <p>Salbutamol inhalers, which may be used in the treatment of primary hyperkalemic periodic paralysis, should be avoided because of the potential for exacerbation of cardiac arrhythmias.</p>
          <p>Thiazide and other potassium-wasting diuretics may provoke drug-induced hypokalemia and could aggravate the QT interval.</p>
        </sec>
        <sec id="acpp.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate relatives at risk in order to identify as early as possible those who would benefit from initiation of treatment and preventive measures:</p>
          <list list-type="bullet">
            <list-item>
              <p>If the pathogenic variant in the family is known, molecular genetic testing can be used to clarify the genetic status of at-risk relatives.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant in the family is not known, detailed neurologic and cardiologic evaluation, 12-lead ECG, and 24-hour Holter monitoring can be used to clarify the disease status of at-risk relatives.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="acpp.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="acpp.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>The rarity of ATS and the paucity of reports pertaining to pregnancy in women with ATS make an evidence-based approach to pregnancy management difficult to formulate. One case study reported an uneventful pregnancy, with increased episodes of weakness but reduced ventricular ectopy compared to the pre-pregnancy period [<xref ref-type="bibr" rid="acpp.REF.subbiah.2008.987">Subbiah et al 2008</xref>]. However, as data are limited, a multidisciplinary approach to individual care and anticipation of increased risk (as can be seen in those with long QT syndrome) seems reasonable.</p>
        </sec>
        <sec id="acpp.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="acpp.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="acpp.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Andersen-Tawil syndrome (ATS) is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="acpp.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At least 50% of individuals diagnosed with ATS have an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with ATS may have the disorder as the result of a <italic toggle="yes">de novo</italic>
<italic toggle="yes">KCNJ2</italic> pathogenic variant. The proportion of cases caused by <italic toggle="yes">de novo</italic> mutation of <italic toggle="yes">KCNJ2</italic> may be as high as 50%.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant include a detailed neurologic and cardiologic evaluation, 12-lead ECG, 24-hour Holter monitoring, and molecular genetic testing for the <italic toggle="yes">KCNJ2</italic> pathogenic variant identified in the proband.</p>
            </list-item>
            <list-item>
              <p>The family history of some individuals diagnosed with ATS may appear to be negative because of failure to recognize the disorder in family members, early death of the parent not attributed to the disease, or reduced penetrance. Therefore, an apparently negative family history cannot be confirmed unless appropriate neurologic and cardiologic evaluations and/or molecular genetic testing has been performed on the parents of the proband.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected and/or has the <italic toggle="yes">KCNJ2</italic> pathogenic variant identified in the proband, the risk to the sibs of inheriting the pathogenic variant is 50%.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">KCNJ2</italic> pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low but greater than that of the general population because of the possibility of germline mosaicism. Germline mosaicism has been reported in ATS [<xref ref-type="bibr" rid="acpp.REF.hasegawa.2015.279">Hasegawa et al 2015</xref>].</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with ATS has a 50% chance of inheriting the <italic toggle="yes">KCNJ2</italic> pathogenic variant.</p>
          <p>
            <bold>Other family members</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to other family members depends on the status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent is affected, his or her family members are at risk.</p>
            </list-item>
          </list>
        </sec>
        <sec id="acpp.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="acpp.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with ATS has the pathogenic variant or clinical evidence of the disorder, the <italic toggle="yes">KCNJ2</italic> pathogenic variant is likely <italic toggle="yes">de novo</italic>. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="acpp.Prenatal_Testing_and_Preimplantatio">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">KCNJ2</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for ATS are possible.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="acpp.Resources">
        <title>Resources</title>
      </sec>
      <sec id="acpp.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p>
          <bold>
            <italic toggle="yes">KCNJ2</italic>
          </bold>
        </p>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">KCNJ2</italic> has two exons spanning 5.4 kb. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="acpp" object-id="acpp.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic variants.</bold> See <related-object source-id="gene" document-id="acpp" object-id="acpp.molgen.TA">Table A</related-object>, <bold>Locus Specific</bold> and <bold>HGMD</bold>. The p.Arg218Trp pathogenic variant is considered a potential hot spot for pathogenic variants [<xref ref-type="bibr" rid="acpp.REF.davies.2005.1083">Davies et al 2005</xref>]. The majority of pathogenic variants in <italic toggle="yes">KCNJ2</italic> are missense changes. A small number of in-frame deletions and a duplication have also been reported.</p>
        <table-wrap id="acpp.T.kcnj2_pathogenic_variants_discuss" orientation="portrait" position="anchor">
          <label>Table 2. </label>
          <caption>
            <p><italic toggle="yes">KCNJ2</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                <th id="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.199C&#x0003e;T</td>
                <td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg67Trp&#x000a0;<sup>1</sup></td>
                <td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_3" rowspan="3" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000891.2">NM_000891.2</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000882.1">NP_000882.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.271_282del12</td>
                <td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala91_Leu94del&#x000a0;<sup>1</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.652C&#x0003e;T</td>
                <td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg218Trp&#x000a0;<sup>2</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.899G&#x0003e;A</td>
                <td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly300Asp&#x000a0;<sup>2</sup></td>
                <td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.953A&#x0003e;G</td>
                <td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asn318Ser&#x000a0;<sup>1</sup></td>
                <td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.966G&#x0003e;C</td>
                <td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Trp322Cys&#x000a0;<sup>1</sup></td>
                <td headers="hd_h_acpp.T.kcnj2_pathogenic_variants_discuss_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="acpp.TF.2.1">
              <label>1. </label>
              <p>See <xref ref-type="sec" rid="acpp.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>.</p>
            </fn>
            <fn id="acpp.TF.2.2">
              <label>2. </label>
              <p>See <xref ref-type="sec" rid="acpp.Clinical_Description">Clinical Description</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">KCNJ2</italic> encodes the inward rectifier potassium channel 2 protein (Kir2.1), with 427 amino acid residues and 48-kd molecular weight. Kir2.1 is expressed primarily in skeletal muscle, heart, and brain. Kir2.1 is involved in setting and stabilizing the resting membrane potential in skeletal and cardiac muscle and has a major role in the terminal repolarization phase of the cardiac action potential [<xref ref-type="bibr" rid="acpp.REF.plaster.2001.511">Plaster et al 2001</xref>, <xref ref-type="bibr" rid="acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</xref>].</p>
        <p><bold>Abnormal gene product.</bold> Pathogenic variants in <italic toggle="yes">KCNJ2</italic> cause dominant-negative suppression of Kir2.1 current [<xref ref-type="bibr" rid="acpp.REF.plaster.2001.511">Plaster et al 2001</xref>, <xref ref-type="bibr" rid="acpp.REF.tristanifirouzi.2002.381">Tristani-Firouzi et al 2002</xref>, <xref ref-type="bibr" rid="acpp.REF.lange.2003.321">Lange et al 2003</xref>, <xref ref-type="bibr" rid="acpp.REF.donaldson.2004.92">Donaldson et al 2004</xref>, <xref ref-type="bibr" rid="acpp.REF.davies.2005.1083">Davies et al 2005</xref>, <xref ref-type="bibr" rid="acpp.REF.ballester.2006.388">Ballester et al 2006</xref>, <xref ref-type="bibr" rid="acpp.REF.barajasmartinez.2011.51">Barajas-Martinez et al 2011</xref>, <xref ref-type="bibr" rid="acpp.REF.marrus.2011.500">Marrus et al 2011</xref>] and affect channel-PIP<sub>2</sub> interactions [<xref ref-type="bibr" rid="acpp.REF.donaldson.2003.1811">Donaldson et al 2003</xref>]. Several pathogenic variants affect trafficking of the mutant channel to the cell surface for reasons that are not clear [<xref ref-type="bibr" rid="acpp.REF.ballester.2006.388">Ballester et al 2006</xref>]. One study identified loss of an endoplasmic reticulum export motif [<xref ref-type="bibr" rid="acpp.REF.doi.2011.253">Doi et al 2011</xref>]. The majority traffic normally to the cell surface but fail to conduct normally [<xref ref-type="bibr" rid="acpp.REF.bendahhou.2003.51779">Bendahhou et al 2003</xref>]. Phosphatidylinositol 4,5 bisphosphate (PIP<sub>2</sub>) is an important regulator of Kir2.1 channel function; many <italic toggle="yes">KCNJ2</italic> pathogenic variants alter PIP<sub>2</sub> binding [<xref ref-type="bibr" rid="acpp.REF.lopes.2002.933">Lopes et al 2002</xref>, <xref ref-type="bibr" rid="acpp.REF.donaldson.2003.1811">Donaldson et al 2003</xref>].</p>
        <p>Flaccid paralysis results from failure to propagate action potentials in the muscle membrane as a result of sustained membrane depolarization [<xref ref-type="bibr" rid="acpp.REF.cannon.2002.533">Cannon 2002</xref>]. The modestly prolonged QT interval and ventricular arrhythmias are caused by impaired cardiac ventricular repolarization; the reduced inward rectifying potassium current results in distinct T-U wave morphology [<xref ref-type="bibr" rid="acpp.REF.tristanifirouzi.2001.50">Tristani-Firouzi et al 2001</xref>, <xref ref-type="bibr" rid="acpp.REF.zhang.2005.2720">Zhang et al 2005</xref>].</p>
        <p>While the role of Kir2.1 in skeletal development remains to be clarified, consistent craniofacial, dental, and skeletal anomalies are present [<xref ref-type="bibr" rid="acpp.REF.yoon.2006a.312">Yoon et al 2006a</xref>].</p>
        <p>Targeted disruption of Kir2.1 in a knockout mouse is fatal, with complete cleft of the secondary palate [<xref ref-type="bibr" rid="acpp.REF.zaritsky.2000.160">Zaritsky et al 2000</xref>].</p>
        <p>
          <bold>
            <italic toggle="yes">KCNJ5</italic>
          </bold>
        </p>
        <p><bold>Pathogenic variants.</bold> One individual with clinical criteria of ATS and a novel pathogenic variant in <italic toggle="yes">KCNJ5</italic> (p.Gly387Arg) has been described. The proband had periodic paralysis and ventricular arrhythmias, with a family history of ventricular arrhythmias on his father&#x02019;s side. A review of 21 individuals in a Japanese cohort (in whom ATS was suspected but no <italic toggle="yes">KCNJ2</italic> pathogenic variant was found) idenitifed one additional patient with a novel variant in <italic toggle="yes">KCNJ5</italic> (p.Thr158Ala) [<xref ref-type="bibr" rid="acpp.REF.kokunai.2014.1058">Kokunai et al 2014</xref>]. The ultimate frequency of <italic toggle="yes">KCNJ5</italic> pathogenic variants in patients who meet clinical criteria for ATS but do not have a <italic toggle="yes">KCNJ2</italic> variant remains to be determined.</p>
        <table-wrap id="acpp.T.kcnj5_pathogenic_variants_discuss" orientation="portrait" position="anchor">
          <label>Table 3. </label>
          <caption>
            <p><italic toggle="yes">KCNJ5</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_acpp.T.kcnj5_pathogenic_variants_discuss_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_acpp.T.kcnj5_pathogenic_variants_discuss_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                <th id="hd_h_acpp.T.kcnj5_pathogenic_variants_discuss_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_acpp.T.kcnj5_pathogenic_variants_discuss_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.472A&#x0003e;G</td>
                <td headers="hd_h_acpp.T.kcnj5_pathogenic_variants_discuss_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr158Ala</td>
                <td headers="hd_h_acpp.T.kcnj5_pathogenic_variants_discuss_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000890.3">NM_000890.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000881.3">NP_000881.3</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_acpp.T.kcnj5_pathogenic_variants_discuss_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1159G&#x0003e;C</td>
                <td headers="hd_h_acpp.T.kcnj5_pathogenic_variants_discuss_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly387Arg</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">KCNJ5</italic> codes a G-protein activated inwardly rectifying potassium channel protein 4 (Kir3.4). Expression studies show that <italic toggle="yes">KCNJ5</italic> is expressed in cardiac and skeletal muscle.</p>
        <p><bold>Abnormal gene product.</bold> Functional studies on the p.Gly387Arg pathogenic variant in <italic toggle="yes">KCNJ5</italic> also demonstrated a dominant-negative effect on Kir2.1 function [<xref ref-type="bibr" rid="acpp.REF.kokunai.2014.1058">Kokunai et al 2014</xref>].</p>
      </sec>
      <sec id="acpp.References">
        <title>References</title>
        <sec id="acpp.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="acpp.Literature_Cited.reflist0">
            <ref id="acpp.REF.ai.2002.2592">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ai</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujiwara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuji</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otani</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakano</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kubo</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horie</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Novel KCNJ2 mutation in familial periodic paralysis with ventricular dysrhythmia.</article-title>
                <source>Circulation.</source>
                <year>2002</year>
                <volume>105</volume>
                <fpage>2592</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">12045162</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.airey.2009.1814">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Airey</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Etheridge</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tawil</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tristani-Firouzi</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Resuscitated sudden cardiac death in Andersen-Tawil syndrome.</article-title>
                <source>Heart Rhythm.</source>
                <year>2009</year>
                <volume>6</volume>
                <fpage>1814</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19959136</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.andelfinger.2002.663">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Andelfinger</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tapper</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Welch</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanoye</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>George</surname>
                    <given-names>AL</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>DW</given-names>
                  </name>
                </person-group>
                <article-title>KCNJ2 mutation results in Andersen syndrome with sex-specific cardiac and skeletal muscle phenotypes.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2002</year>
                <volume>71</volume>
                <fpage>663</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12148092</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.andersen.1971.559">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Andersen</surname>
                    <given-names>ED</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krasilnikoff</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Overvad</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Intermittent muscular weakness, extrasystoles, and multiple developmental anomalies. A new syndrome?</article-title>
                <source>Acta Paediatr Scand.</source>
                <year>1971</year>
                <volume>60</volume>
                <fpage>559</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">4106724</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.ballester.2006.388">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ballester</surname>
                    <given-names>LY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Law</surname>
                    <given-names>IH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mathews</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanoye</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>George</surname>
                    <given-names>AL</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <article-title>Trafficking-competent and trafficking-defective KCNJ2 mutations in Andersen syndrome.</article-title>
                <source>Hum Mutat.</source>
                <year>2006</year>
                <volume>27</volume>
                <fpage>388</fpage>
                <pub-id pub-id-type="pmid">16541386</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.barajasmartinez.2011.51">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Barajas-Martinez</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hu</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ontiveros</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caceres</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desai</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burashnikov</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scaglione</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antzelevitch</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Biophysical and molecular characterization of a novel de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry.</article-title>
                <source>Circ Cardiovasc Genet.</source>
                <year>2011</year>
                <volume>4</volume>
                <fpage>51</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21148745</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.bendahhou.2003.51779">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bendahhou</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donaldson</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plaster</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tristani-Firouzi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fu</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pt&#x000e1;cek</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <article-title>Defective potassium channel Kir2.1 trafficking underlies Andersen-Tawil syndrome.</article-title>
                <source>J Biol Chem.</source>
                <year>2003</year>
                <volume>278</volume>
                <fpage>51779</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">14522976</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.b_kenkamp.2007.508">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>B&#x000f6;kenkamp</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilde</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schalij</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blom</surname>
                    <given-names>NA</given-names>
                  </name>
                </person-group>
                <article-title>Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome.</article-title>
                <source>Heart Rhythm.</source>
                <year>2007</year>
                <volume>4</volume>
                <fpage>508</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">17399642</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.cannon.2002.533">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cannon</surname>
                    <given-names>SC</given-names>
                  </name>
                </person-group>
                <article-title>An expanding view for the molecular basis of familial periodic paralysis.</article-title>
                <source>Neuromuscul Disord.</source>
                <year>2002</year>
                <volume>12</volume>
                <fpage>533</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">12117476</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.can_n.1999.147">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Can&#x000fa;n</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;rez</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beirana</surname>
                    <given-names>LG</given-names>
                  </name>
                </person-group>
                <article-title>Andersen syndrome autosomal dominant in three generations.</article-title>
                <source>Am J Med Genet.</source>
                <year>1999</year>
                <volume>85</volume>
                <fpage>147</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">10406668</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.chun.2004.235">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chun</surname>
                    <given-names>TU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Epstein</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dick</surname>
                    <given-names>M</given-names>
                    <suffix>2nd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Andelfinger</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ballester</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanoye</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>George</surname>
                    <given-names>AL</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>DW</given-names>
                  </name>
                </person-group>
                <article-title>Polymorphic ventricular tachycardia and KCNJ2 mutations.</article-title>
                <source>Heart Rhythm.</source>
                <year>2004</year>
                <volume>1</volume>
                <fpage>235</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">15851159</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.davies.2005.1083">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>NP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imbrici</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fialho</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herd</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bilsland</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mueller</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hilton-Jones</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ealing</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boothman</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giunti</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parsons</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manzur</surname>
                    <given-names>AY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jurkat-Rott</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehmann-Horn</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinnery</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rose</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kullmann</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>MG</given-names>
                  </name>
                </person-group>
                <article-title>Andersen-Tawil syndrome: new potassium channel mutations and possible phenotypic variation.</article-title>
                <source>Neurology.</source>
                <year>2005</year>
                <volume>65</volume>
                <fpage>1083</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16217063</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.delannoy.2013.1805">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Delannoy</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sacher</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maury</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mabo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mansourati</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magnin</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camous</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tournant</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rendu</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kyndt</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ha&#x000ef;ssaguerre</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000e9;zieau</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guyomarch</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Marec</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fressart</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Denjoy</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Probst</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <article-title>Cardiac characteristics and long-term outcome in Andersen-Tawil syndrome patients related to KCNJ2 mutation.</article-title>
                <source>Europace.</source>
                <year>2013</year>
                <volume>15</volume>
                <fpage>1805</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">23867365</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.doi.2011.253">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Doi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makiyama</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morimoto</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haruna</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuji</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohno</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akao</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimura</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horie</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>A novel KCNJ2 nonsense mutation, S369X, impedes trafficking and causes a limited form of Andersen-Tawil syndrome.</article-title>
                <source>Circ Cardiovasc Genet.</source>
                <year>2011</year>
                <volume>4</volume>
                <fpage>253</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">21493816</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.donaldson.2003.1811">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Donaldson</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jensen</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tristani-Firouzi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tawil</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bendahhou</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suarez</surname>
                    <given-names>WA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cobo</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poza</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Behr</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wagstaff</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szepetowski</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pereira</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mozaffar</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Escolar</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fu</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pt&#x000e1;cek</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <article-title>PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome.</article-title>
                <source>Neurology.</source>
                <year>2003</year>
                <volume>60</volume>
                <fpage>1811</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12796536</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.donaldson.2004.92">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Donaldson</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoon</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fu</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ptacek</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <article-title>Andersen-Tawil syndrome: a model of clinical variability, pleiotropy, and genetic heterogeneity.</article-title>
                <source>Ann Med.</source>
                <year>2004</year>
                <volume>36</volume>
                <supplement>Suppl 1</supplement>
                <fpage>92</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15176430</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.fernlund.2013.471">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fernlund</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lundin</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hertervig</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kongstad</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alders</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Platonov</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Novel mutation in the KCNJ2 gene is associated with a malignant arrhythmic phenotype of Andersen-Tawil syndrome.</article-title>
                <source>Ann Noninvasive Electrocardiol.</source>
                <year>2013</year>
                <volume>18</volume>
                <fpage>471</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">24047492</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.fournier.2004.650">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fournier</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arzel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sternberg</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vicart</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laforet</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eymard</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willer</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tabti</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fontaine</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Electromyography guides toward subgroups of mutations in muscle channelopathies.</article-title>
                <source>Ann Neurol.</source>
                <year>2004</year>
                <volume>56</volume>
                <fpage>650</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">15389891</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.fox.2008.1006">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fox</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hahn</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skanes</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gula</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yee</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Subbiah</surname>
                    <given-names>RN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krahn</surname>
                    <given-names>AD</given-names>
                  </name>
                </person-group>
                <article-title>Reduction of complex ventricular ectopy and improvement in exercise capacity with flecainide therapy in Andersen-Tawil syndrome.</article-title>
                <source>Europace.</source>
                <year>2008</year>
                <volume>10</volume>
                <fpage>1006</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">18621769</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.haruna.2007.208">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Haruna</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobori</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makiyama</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akao</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuji</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ono</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishio</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inoue</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murakami</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuboi</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamanouchi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ushinohama</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshinaga</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horigome</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aizawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kita</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horie</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Genotype-phenotype correlations of KCNJ2 mutations in Japanese patients with Andersen-Tawil syndrome.</article-title>
                <source>Hum Mutat.</source>
                <year>2007</year>
                <volume>28</volume>
                <fpage>208</fpage>
                <pub-id pub-id-type="pmid">17221872</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.hasegawa.2015.279">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hasegawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohno</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itoh</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makiyama</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horie</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Mosaic KCNJ2 mutation in Andersen-Tawil syndrome: targeted deep sequencing is useful for the detection of mosaicism.</article-title>
                <source>Clin Genet.</source>
                <year>2015</year>
                <volume>87</volume>
                <fpage>279</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">24635491</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.hosaka.2003.409">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hosaka</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanawa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Washizuka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinushi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamashita</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Komura</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watanabe</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aizawa</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>Function, subcellular localization and assembly of a novel mutation of KCNJ2 in Andersen's syndrome.</article-title>
                <source>J Mol Cell Cardiol.</source>
                <year>2003</year>
                <volume>35</volume>
                <fpage>409</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">12689820</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.katz.1999.352">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Katz</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolfe</surname>
                    <given-names>GI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iannaccone</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryan</surname>
                    <given-names>WW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barohn</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>The exercise test in Andersen syndrome.</article-title>
                <source>Arch Neurol.</source>
                <year>1999</year>
                <volume>56</volume>
                <fpage>352</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10190827</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.kimura.2012.344">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kimura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawamura</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itoh</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizusawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ding</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohno</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makiyama</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyamoto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naiki</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xie</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tateno</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zang</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horie</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Phenotype variability in patients carrying KCNJ2 mutations.</article-title>
                <source>Circ Cardiovasc Genet.</source>
                <year>2012</year>
                <volume>5</volume>
                <fpage>344</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">22589293</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.kokunai.2014.1058">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kokunai</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakata</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furuta</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakata</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aiba</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshinaga</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osaki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamori</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itoh</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sato</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kubota</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kadota</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shindo</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mochizuki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horie</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okamura</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohno</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>MP</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>A Kir3.4 mutation causes Andersen-Tawil syndrome by an inhibitory effect on Kir2.1.</article-title>
                <source>Neurology.</source>
                <volume>82</volume>
                <fpage>1058</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">24574546</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.kuntzer.2000.1089">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kuntzer</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flocard</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vial</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohler</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magistris</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Labarre-Vila</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonnaud</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ochsner</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soichot</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monnier</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Exercise test in muscle channelopathies and other muscle disorders.</article-title>
                <source>Muscle Nerve.</source>
                <year>2000</year>
                <volume>23</volume>
                <fpage>1089</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">10883004</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.lange.2003.321">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lange</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Er</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gassanov</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoppe</surname>
                    <given-names>UC</given-names>
                  </name>
                </person-group>
                <article-title>Andersen mutations of KCNJ2 suppress the native inward rectifier current IK1 in a dominant-negative fashion.</article-title>
                <source>Cardiovasc Res.</source>
                <year>2003</year>
                <volume>59</volume>
                <fpage>321</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12909315</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.lestner.2012.700">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lestner</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellis</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Canham</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Delineating the 17q24.2-q24.3 microdeletion syndrome phenotype.</article-title>
                <source>Eur J Med Genet.</source>
                <year>2012</year>
                <volume>55</volume>
                <fpage>700</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">22982078</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.limberg.2013.353">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Limberg</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zumhagen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Netter</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coffey</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grace</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rogers</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000f6;ckelmann</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinn&#x000e9;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stallmeyer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Decher</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schulze-Bahr</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Non dominant-negative KCNJ2 gene mutations leading to Andersen-Tawil syndrome with an isolated cardiac phenotype.</article-title>
                <source>Basic Res Cardiol.</source>
                <year>2013</year>
                <volume>108</volume>
                <fpage>353</fpage>
                <pub-id pub-id-type="pmid">23644778</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.lopes.2002.933">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lopes</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rohacs</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jin</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Logothetis</surname>
                    <given-names>DE</given-names>
                  </name>
                </person-group>
                <article-title>Alterations in conserved Kir channel-PIP2 interactions underlie channelopathies.</article-title>
                <source>Neuron.</source>
                <year>2002</year>
                <volume>34</volume>
                <fpage>933</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">12086641</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.marquisnicholson.2014.17">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marquis-Nicholson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prosser</surname>
                    <given-names>DO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Love</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayes</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>George</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crawford</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skinner</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Love</surname>
                    <given-names>DR</given-names>
                  </name>
                </person-group>
                <article-title>Array comparative genomic hybridization identifies a heterozygous deletion of the entire KCNJ2 gene as a cause of sudden cardiac death.</article-title>
                <source>Circ Cardiovasc Genet.</source>
                <year>2014</year>
                <volume>7</volume>
                <fpage>17</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">24395924</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.marrus.2011.500">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marrus</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cuculich</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nerbonne</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <article-title>Characterization of a novel, dominant negative KCNJ2 mutation associated with Andersen-Tawil syndrome.</article-title>
                <source>Channels (Austin)</source>
                <year>2011</year>
                <volume>5</volume>
                <fpage>500</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22186697</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.miyamoto.2015.596">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miyamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aiba</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohno</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasuoka</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanioka</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuchiya</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuboi</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakajima</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishibashi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okamura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishihara</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anzai</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasuda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyamoto</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamakura</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kusano</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogawa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horie</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>W.</given-names>
                  </name>
                </person-group>
                <article-title>Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations.</article-title>
                <source>Heart Rhythm.</source>
                <year>2015</year>
                <volume>12</volume>
                <fpage>596</fpage>
                <lpage>603</lpage>
                <pub-id pub-id-type="pmid">25496985</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.pellizz_n.2008.95">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pellizz&#x000f3;n</surname>
                    <given-names>OA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalaizich</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pt&#x000e1;cek</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tristani-Firouzi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonzalez</surname>
                    <given-names>MD</given-names>
                  </name>
                </person-group>
                <article-title>Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome.</article-title>
                <source>J Cardiovasc Electrophysiol.</source>
                <year>2008</year>
                <volume>19</volume>
                <fpage>95</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17655675</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.plaster.2001.511">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Plaster</surname>
                    <given-names>NM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tawil</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tristani-Firouzi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Can&#x000fa;n</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bendahhou</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsunoda</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donaldson</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iannaccone</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunt</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barohn</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deymeer</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>George</surname>
                    <given-names>AL</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Fish</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hahn</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nitu</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozdemir</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serdaroglu</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Subramony</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolfe</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fu</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pt&#x000e1;cek</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome.</article-title>
                <source>Cell.</source>
                <year>2001</year>
                <volume>105</volume>
                <fpage>511</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11371347</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.ryan.2010.88">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ryan</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>da Silva</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soong</surname>
                    <given-names>TW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fontaine</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donaldson</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kung</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jongjaroenprasert</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liang</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khoo</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheah</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ho</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernstein</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maciel</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>RH</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Pt&#x000e1;cek</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis.</article-title>
                <source>Cell.</source>
                <year>2010</year>
                <volume>140</volume>
                <fpage>88</fpage>
                <lpage>98</lpage>
                <pub-id pub-id-type="pmid">20074522</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.sansone.1997.305">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sansone</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griggs</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meola</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pt&#x000e1;cek</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barohn</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iannaccone</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bryan</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baker</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janas</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ririe</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tawil</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Andersen's syndrome: a distinct periodic paralysis.</article-title>
                <source>Ann Neurol.</source>
                <year>1997</year>
                <volume>42</volume>
                <fpage>305</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">9307251</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.schoonderwoerd.2006.1346">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schoonderwoerd</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiesfeld</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilde</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Heuvel</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Tintelen</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Berg</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Veldhuisen</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Gelder</surname>
                    <given-names>IC</given-names>
                  </name>
                </person-group>
                <article-title>A family with Andersen-Tawil syndrome and dilated cardiomyopathy.</article-title>
                <source>Heart Rhythm.</source>
                <year>2006</year>
                <volume>3</volume>
                <fpage>1346</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">17074642</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.subbiah.2008.987">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Subbiah</surname>
                    <given-names>RN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gula</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Skanes</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krahn</surname>
                    <given-names>AD</given-names>
                  </name>
                </person-group>
                <article-title>Andersen-Tawil syndrome: management challenges during pregnancy, labor, and delivery.</article-title>
                <source>J Cardiovasc Electrophysiol.</source>
                <year>2008</year>
                <volume>19</volume>
                <fpage>987</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18554214</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.tan.2011.328">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tan</surname>
                    <given-names>SV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matthews</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barber</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burge</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rajakulendran</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fialho</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sud</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haworth</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koltzenburg</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>MG</given-names>
                  </name>
                </person-group>
                <article-title>Refined exercise testing can aid DNA-based diagnosis in muscle channelopathies.</article-title>
                <source>Ann Neurol.</source>
                <year>2011</year>
                <volume>69</volume>
                <fpage>328</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">21387378</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.tawil.1994.326">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tawil</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ptacek</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pavlakis</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeVivo</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penn</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozdemir</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griggs</surname>
                    <given-names>RC</given-names>
                  </name>
                </person-group>
                <article-title>Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features.</article-title>
                <source>Ann Neurol.</source>
                <year>1994</year>
                <volume>35</volume>
                <fpage>326</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">8080508</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.tristanifirouzi.2001.50">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tristani-Firouzi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitcheson</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanguinetti</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <article-title>Molecular biology of K(+) channels and their role in cardiac arrhythmias.</article-title>
                <source>Am J Med.</source>
                <year>2001</year>
                <volume>110</volume>
                <fpage>50</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11152866</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.tristanifirouzi.2010.289">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tristani-Firouzi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Etheridge</surname>
                    <given-names>SP</given-names>
                  </name>
                </person-group>
                <article-title>Kir 2.1 channelopathies: the Andersen-Tawil syndrome.</article-title>
                <source>Pflugers Arch.</source>
                <year>2010</year>
                <volume>460</volume>
                <fpage>289</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">20306271</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.tristanifirouzi.2002.381">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tristani-Firouzi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jensen</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donaldson</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sansone</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meola</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hahn</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bendahhou</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kwiecinski</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fidzianska</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plaster</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fu</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ptacek</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tawil</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome).</article-title>
                <source>J Clin Invest.</source>
                <year>2002</year>
                <volume>110</volume>
                <fpage>381</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12163457</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.tristanifirouzi.2006.1351">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tristani-Firouzi</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Andersen-Tawil syndrome: an ever-expanding phenotype?</article-title>
                <source>Heart Rhythm.</source>
                <year>2006</year>
                <volume>3</volume>
                <fpage>1351</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">17074643</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.vergult.2012.534">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vergult</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dauber</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delle Chiaie</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Oudenhove</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simon</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rihani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loeys</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirschhorn</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pfotenhauer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phillips</surname>
                    <given-names>JA</given-names>
                    <suffix>3rd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Mohammed</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogilvie</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crolla</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mortier</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menten</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>17q24.2 microdeletions: a new syndromal entity with intellectual disability, truncal obesity, mood swings and hallucinations.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2012</year>
                <volume>20</volume>
                <fpage>534</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22166941</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.yoon.2006a.312">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yoon</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oberoi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tristani-Firouzi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Etheridge</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quitania</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kramer</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fu</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pt&#x000e1;cek</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <article-title>Andersen-Tawil syndrome: prospective cohort analysis and expansion of the phenotype.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2006a</year>
                <volume>140</volume>
                <fpage>312</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">16419128</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.yoon.2006b.1703">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yoon</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quitania</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kramer</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fu</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pt&#x000e1;cek</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <article-title>Andersen-Tawil syndrome: definition of a neurocognitive phenotype.</article-title>
                <source>Neurology.</source>
                <year>2006b</year>
                <volume>66</volume>
                <fpage>1703</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">16769944</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.zaritsky.2000.160">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zaritsky</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eckman</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wellman</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarz</surname>
                    <given-names>TL</given-names>
                  </name>
                </person-group>
                <article-title>Targeted disruption of Kir2.1 and Kir2.2 genes reveals the essential role of the inwardly rectifying K(+) current in K(+)-mediated vasodilation.</article-title>
                <source>Circ Res.</source>
                <year>2000</year>
                <volume>87</volume>
                <fpage>160</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">10904001</pub-id>
              </element-citation>
            </ref>
            <ref id="acpp.REF.zhang.2005.2720">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benson</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tristani-Firouzi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ptacek</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tawil</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>George</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horie</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andelfinger</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snow</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fu</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ackerman</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vincent</surname>
                    <given-names>GM</given-names>
                  </name>
                </person-group>
                <article-title>Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype.</article-title>
                <source>Circulation.</source>
                <year>2005</year>
                <volume>111</volume>
                <fpage>2720</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15911703</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="acpp.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="acpp.Suggested_Reading.reflist0">
            <ref id="acpp.REF.venance.2006.8">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Venance</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cannon</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fialho</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fontaine</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ptacek</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tristani-Firouzi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tawil</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griggs</surname>
                    <given-names>RC</given-names>
                  </name>
                  <collab>CINCH investigators</collab>
                </person-group>
                <article-title>The primary periodic paralyses: diagnosis, pathogenesis and treatment.</article-title>
                <source>Brain.</source>
                <year>2006</year>
                <volume>129</volume>
                <fpage>8</fpage>
                <lpage>17</lpage>
                <pub-id pub-id-type="pmid">16195244</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="acpp.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="acpp.Acknowledgments">
          <title>Acknowledgments</title>
          <p>The authors are funded in part by the Consortium for Clinical Investigation of Neurological Channelopathies (CINCH) supported by NIH 8 U54 NS59065 (NINDS/ORD).</p>
        </sec>
        <sec id="acpp.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>3 September 2015 (rt) Revision: <xref ref-type="sec" rid="acpp.Treatment_of_Manifestations">Treatment of Manifestations</xref></p>
            </list-item>
            <list-item>
              <p>6 August 2015 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>3 January 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>13 May 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>19 March 2007 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>27 April 2005 (cd) Revision: prenatal diagnosis available</p>
            </list-item>
            <list-item>
              <p>22 November 2004 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>1 June 2004 (rt) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
